1 New Approaches to Monitoring Heart Failure Before Symptoms Appear William T. Abraham, MD, FACP, FACC Professor of Medicine Chief, Division of Cardiovascular.

Slides:



Advertisements
Similar presentations
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Advertisements

Girish Singhania N Engl J Med 2012 Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome.
Chapter 20 Heart Failure.
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.
Myocardial Ischemia: An Underrated Cause of Sudden Cardiac Death?
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Intracoronary Autologous Bone-Marrow Cell Transfer after Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Presented.
The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Simulation training Curriculum Pericardial Disease.
Stages of CKD – KDOQI 2002 Definitions
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Case Studies in Advanced Monitoring: OptiVol
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Heart Failure, HF CHF develops when plasma volume increases and fluid accumulates in the lungs, abdominal organs (liver especially), and peripheral tissues.
Ventricular Diastolic Filling and Function
Orlando, Florida – October 7, 2011 Cardiac Rehab: Improving Outcomes One Step at a Time Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Integrating Monitoring into the Infrastructure and Workflow of Routine Practice: OptiVol Roy S. Small, MD, FACC Director, Heart Failure Clinic, The Heart.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Supporting Patients with CHF Care Transformation Collaborative of R.I. MAUREEN CLAFLIN, MSN, RN. NCM UNIVERSITY MEDICINE GOVERNOR STREET PRIMARY CARE CENTER.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Integrating Monitoring into the Infrastructure and Workflow of Routine Practice Philip B. Adamson, MD Associate Professor of Physiology Director, The Heart.
Pulmonary Circulation Dr. Walid Daoud MBBCh, MSc, MD, FCCP Director of Chest Department, Shifa Hospital, A. Professor of Chest Medicine.
Case Studies The results presented in these case studies are specific to these individual patients. Patient results will vary, not every response is the.
Frank-Starling Mechanism
Heart Failure Claire B. Hunter, MD. Heart Failure is the inability of the heart to pump sufficient blood to the body tissue to meet ordinary metabolic.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Acute Heart Failure in Apical Ballooning Syndrome (Takotsubo/Stress Cardiomyopathy) Clinical Correlates and Mayo Clinic Risk Score Malini Madhavan, MBBS;
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
Haissam A Haddad, MD, FRCPC, FACC University of Ottawa Heart Institute
Internal Medicine Workshop Series Laos September /October 2009
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Using Monitoring Devices Systems to Optimize Patient Care Giuseppe Stabile CLINICA MEDITERRANEA MEDITERRANEA.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Eric J Robinson, M.D. Cardiologist April 25, 2015
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Revolutionizing Point of Care with Remote Healthcare Solutions Lance Myers, PhD.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pregnancy in Patients With Pre-Existing Cardiomyopathies.
Alireza Heidari Bakavoli, MD. Cardiology department Qaem medical center Mashhad University of Medical Science Role of ICD and CRT devices in Heart failure.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Conflict of Interest Baxter Research Grant Medtronic Research Grant
William E. Haik, M.D., F.C.C.P. A Clinical Review of the CC/MCC List ©DRG Review, Inc.
David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
Management of mitral regurgitation. See legend for Fig
Optimizing heart failure therapy with implantable sensors
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
Optimal Pacing for Right Ventricular and Biventricular Devices
The Cardiovascular Inflammation Reduction Trial (CIRT)
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Division of Cardiovascular Diseases No relevant author disclosures
Global Registry of Acute Coronary Events: GRACE
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
Maria R. Costanzo et al. JCHF 2016;4:
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Rick A. Nishimura et al. JACC 2017;70:
Presentation transcript:

1 New Approaches to Monitoring Heart Failure Before Symptoms Appear William T. Abraham, MD, FACP, FACC Professor of Medicine Chief, Division of Cardiovascular Medicine Associate Director, Davis Heart & Lung Research Institute The Ohio State University Columbus, Ohio

2 Asymptomatic fluid retention Change in impedance or pressure Worsening heart failure Can Implantable Monitors Predict Worsening Heart Failure? Can this prevent hospitalization for worsening heart failure?

3 Intrathoracic Impedance as a Measure of Heart Failure Clinical Status

4 Impedance “Wetter” Lungs Impedance Decreases With Increasing Lung Wetness

5 Impedance Prior to CHF Admission More Fluid Less Impedance (  ) Days Before Hospitalization Impedance Reduction Duration of Impedance Reduction Reference Baseline CHF, congestive heart failure.

6 Evidence Supporting the Use of Intrathoracic Impedance  Animal studies  Completed MID-HeFT study: Medtronic Impedance Diagnostics in Heart Failure Trial  Ongoing FAST study: Fluid Accumulation Status Trial

7 MID-HeFT Study  MIDHeFT study –33 patients, 628 months of follow-up (as of 9/1/03) –25 hospitalizations for fluid overload from 10 patients –Demonstrated an inverse correlation between impedance and both PCWP and net fluid I/O in patients hospitalized for fluid overload –Demonstrated consistent decreases in impedance in the days preceding hospitalization (ie, predicted hospitalization!) PCWP, pulmonary capillary wedge pressure; I/O, in/out. Yu C-M, et al. Circulation. 2005;112:

8 MID-HeFT Study Results  Intrathoracic impedance decline preceded the onset of symptoms by mean lead time of 10.3 days (P<0.0001)  Retrospective analysis of the clinical data showed that intrathoracic impedances gradually decreased over approximately 2 weeks prior to HF hospitalization (14 days, P<0.0001) with a total reduction of 11.3%  Using a single detection threshold for all patients, the OptiVol algorithm would have detected 76% of admissions for fluid overload, with an average of only one false warning for every 322 days of patient monitoring HF, heart failure Yu C-M, et al. Circulation. 2005;112:

Days In Hospital PCWP (mm Hg) Fluid I/O (liters) Impedance (  ) Example: Fluid Status During Diuresis

Impedance (  ) Reference BaselineOne Day Prior to Admission /- 5.3% (P<0.001) / Days Impedance Leading Up To Admission (n=24)

11 Days Prior to Admission Symptom OnsetImpedance Decline Impedance Decline Precedes Symptoms (n=20)

12 Automated Detection of Decreases in Intrathoracic Impedance That Precede Hospitalization for CHF

13 OptiVol Feature Physician- programmed threshold Reference impedance slowly adapts to daily impedance Daily impedance is the average of one day’s measurements Accumulation of the difference between the daily and reference impedance Jun 98Aug 98 Oct > Jun 98Aug 98 Oct 98 Thoracic Impedance (ohms) Daily Reference OptiVol Fluid Index OptiVol Threshold Fluid P P, program.

Days Fluid Index (  days) Days Impedance (  ) 0 0 Overview of Detection Algorithm

15 FAST Study  FAST study –44 patients enrolled/downloaded –47 months of total follow-up –32 patients to 1 month –7 patients with an HF event; 25 were event-free 3 clinically relevant HF hospitalizations (in 2 patients)* 11 clinically relevant HF medication changes (in 5 patients)* 4 adverse events from HF medication changes (in 4 patients)* –Study corroborated impedance performance from the MID- HeFT study in both event-free and HF event occurrences *Patients with events are not mutually exclusive.

16 FAST Case Study 2 – HF Event H, hospitalization; O, outpatient visit; M, medication change; F, protocol scheduled follow-up. Threshold crossed 19 days prior to hospitalization. Discharged after 1.5 lbs of diuresis Discharged after 10.8 lbs of diuresis Days Impedance Patient HHHHHHH F F MMMMMM Days Cumulative Diff HHHHHHH F F MMMMMM Days Weight (lbs) FF

17 Nov. 5: Lead replacement. Impedance stabilizes several days after procedure. Oct. 28: Hospitalization for decompensation: orthopnea, peripheral edema, and crackles in lower lungs. Sept. 29: Crossed OptiVol fluid threshold. Oct. 7: LV lead dislodgement observed. Decided to reposition lead in November. Sep 04Nov > > Sep 04Nov 04 Thoracic Impedance (ohms) Daily Reference OptiVol Fluid Index OptiVol Threshold Fluid InSync Sentry ™ Case: Loss of CRT CRT, cardiac resynchronization therapy.

18 Aug 04Oct > > Aug 04Oct 04 Thoracic Impedance (ohms) Daily Reference OptiVol Fluid Index OptiVol Threshold Fluid Dec 04 InSync Sentry Case: Precipitous Drop in Impedance

19 Aug 04Oct > > Thoracic Impedance (ohms) Daily Reference Dec <50 AT/AF Total hours/day V. rate during AT/AF (bpm) Max/day Avg/day AT, atrial tachycardia; AF, atrial fibrillation; V. rate, ventricular rate. InSync Sentry Case: Precipitous Drop in Impedance

20 Implantable Hemodynamic Monitoring Systems

21 Implantable Hemodynamic Monitor

22 IHMHome MonitorClinician Access Secure Network  RV systolic pressure  RV diastolic pressure  Estimated PA diastolic pressure  Other parameters IHM System and Information Flow IHM, implantable hemodynamic monitor; RV, right ventricular; PA, pulmonary artery.

23 IHM-Guided Care Reduces Worsening HF in NYHA Class III Patients Cumulative Events Events TCA (n=112) BCA (n=122) Patients With Events (#) 3348 Total HF-Related Events 4989 Hospitalizations 4176 Emergency Department Visits 611 Urgent Clinic Visits 22 Event Rate/ 6 Months Reduction in Event Rate (%) 41% (P=0.03) TCA BCA Months NYHA, New York Heart Association; BCA, blocked clinician access; TCA, total clinician access. Bourge RC, et al. ACC 2005.

24 IHM Case Study  59-year-old white female with ICM –S/P AWMI 2001; CABG 4 SVG 2001  Participant in COMPASS-HF Trial (BCA)  Called 5 days after Valentine’s Day 2005 due to bloating and increased shortness of breath  Weight “stable”  Asked to transmit data ICM, ischemic cardiomyopathy; AWMI, anterior wall myocardial infarction; CABG, coronary artery bypass graft; SVG, saphenous vein graft; BCA, blocked clinician access.

RV Diastolic Pressure (mm Hg) RV Systolic Pressure (mm Hg) ePAD (mm Hg) ePAD, estimated pulmonary artery diastolic pressure.

26 IHM Case Study  Had celebrated Valentine’s Day by going out to eat –At an Indian restaurant! –Very thirsty – increased fluids  Diuretics increased

27 Summary  Long-term trends in intrathoracic impedance may provide an early warning of impending episodes of decompensation in outpatients  Implantable hemodynamic monitoring (IHM) enables the day-to-day management of ventricular filling pressures in CHF patients  Intrathoracic impedance and IHM represent complimentary and promising new technologies for the management of HF